Bioforce Nanosciences Holdings, Inc.
BioForce Nanosciences Holdings, Inc. is a U.S.-based microcap company that has shifted away from its original nanotechnology roots into nutritional supplements. Its current business centers on the BioForce Eclipse powder multivitamin and mineral supplement, which it private-labels through a Virginia manufacturer and distributes through retail and online channels. The company says it is trying to build brand awareness through social media, telemarketing, direct marketing, and B2B sales. It remains in an early commercial stage and has disclosed that it does not yet generate enough revenue to cover operating expenses.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePowdered multivitamin and mineral supplements sold under the BioForce Eclipse brand.
Supplement products manufactured by third parties and sold under private-label arrangements.
Customers
BioForce targets retail and wholesale buyers that can place its supplement products into consumer channels, including retailers, sporting goods stores, supermarkets, mass merchandisers, grocery stores, retail pharmacies, and online marketplaces such as Amazon. It also seeks B2B relationships with distributors and vendor partners that can broaden shelf access and improve product placement. The company explicitly mentions health-conscious individuals and active consumers as the end users of its powders, vitamins, and beverages. It also identifies institutional outlets such as hospitals, medical clinics, universities, nursing homes, prisons, and other facilities as potential sales channels for its vitamin and mineral products.
Retailers, grocery stores, pharmacies, and mass merchandisers that buy supplement products for resale because they want branded wellness items with consumer demand.
E-commerce channels such as Amazon that buy or list the product to reach consumers directly and broaden geographic reach.
Distributors and vendor partners that help place the product into multiple outlets and support the company's direct marketing strategy.
Hospitals, clinics, universities, nursing homes, prisons, and similar facilities that may purchase vitamin and mineral supplements for on-site use or resale.
Health-conscious and active individuals who consume the Eclipse powder and related supplements for nutrition support.
Strategy
BioForce's near-term strategy is to build a viable supplement business around BioForce Eclipse and related nutritional products after exiting its earlier nanotechnology business. Management is focused on brand awareness, direct marketing, telemarketing, social media, and B2B sales to secure retail placements and online demand. The company also wants to improve sourcing economics by evaluating alternative manufacturing arrangements if it can maintain quality. Because the business is undercapitalized and not yet self-funding, raising working capital is a central strategic requirement for survival and execution.
The company needs consumer awareness to create pull-through demand and convince retailers to carry the product.
Broader retail and online distribution is necessary to scale sales beyond a limited set of outlets.
The company wants to reduce product cost and improve economics while maintaining quality.
The company has disclosed insufficient revenues and ongoing cash needs, making financing essential to continue operations.
Geography
The company is headquartered in the United States and describes the U.S. as its core and intended expansion market. Management says it plans to expand marketing throughout the entire United States, which makes domestic distribution and brand-building the main geographic priorities. It currently sources private-label production from a manufacturer located in Virginia, so its supply chain is also U.S.-based. No country-level revenue disclosure was provided in the excerpts, and the business appears to be concentrated in the domestic market.
Risks
The most immediate risk is going concern and liquidity risk, because management states that the company does not have sufficient revenues to pay operating expenses and may need to cease operations or substantially change its business plan if it cannot raise capital. Commercial execution risk is also high because the company is still building brand awareness and has not yet established stable demand or broad distribution for its supplement products. Supply-chain and counterparty risk matter because the company relies on a third-party manufacturer and a private-label arrangement, which can affect cost, availability, and control over the product formula. More broadly, the supplement industry faces regulatory, quality, and consumer-preference risks, and the company is exposed to competition from larger brands with stronger distribution and marketing budgets.
Management states that the company does not have sufficient revenues to cover operating expenses and needs additional capital to continue operations.
Exposure: Entire business
Recent cash inflows came from related parties and capital contributions, indicating the business depends on non-operating funding.
Exposure: Cash flow and continuity
The company is still trying to establish brand awareness and reported no orders in one disclosed quarter, showing uncertain demand.
Exposure: Revenue generation
The product is manufactured by an outside supplier and the distributor owns the formula rights, limiting control over supply and economics.
Exposure: Product availability and margins
Dietary supplements are subject to FDA rules and quality expectations, which can affect market access and liability.
Exposure: Compliance and reputation
Accounting
Judgemental itemsThe company recognizes revenue when control transfers, and consignment/private-label arrangements can affect the timing of recognition.
Impact: Can shift reported sales between periods
Management identifies impairment as a critical policy, which is important if assets tied to prior or current business lines are not recoverable.
Impact: Can create material non-cash charges
Board and officer compensation accruals and accounts payable are significant relative to the company's scale.
Impact: Affects liabilities, expenses, and cash flow
The company states it may need to cease operations or change its business plan without additional capital.
Impact: Important for valuation and financial statement interpretation
Similar listed companies
Publicly listed companies with a comparable business focus.
Bio Essence Corp
BIOE · Pharmaceutical Preparations
Bio Essence Corp is a California-based holding company whose operating history has centered on health supplements and OEM manufacturing/distribution services.
CapForce Inc.
CFOR · Services-Medical Laboratories
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Nanoform Finland Oyj
NANOFH · Biotechnology
Nanoform Finland is a Finnish company specializing in nanotechnology and pharmaceutical particle engineering services.
NanoViricides, Inc
NNVC · Pharmaceutical Preparations
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Last updated: 24/09/2026